MAGE-A1, MAGE-A3/4 and NY-ESO-1 have been applied for clinical trials of vaccine immunotherapy for multiple cancer patients, selleck chemicals llc but the utility of CTA immunotherapy against patients with IHCC remains investigated. In this study, using three CTA markers MAGE-A1, MAGE-A3/4 and NY-ESO-1, we identified a subgroup (58.4%) of IHCC patients with at least one CTA expression having a poor prognosis. Moreover, high levels of expression of these antigens were observed in most positive cases. In our study, the concomitant expression of CTAs and HLA class I antigen was observed in 33.7% of the IHCC tumors, which indicating that it
may be possible to immunise a significant proportion of IHCC patients with tumor-specific CTLs. Based on our data, we suggest that a considerable
number of IHCC patients at high-risk might benefit from specific immunotherapy targeted MAGE-A and NY-ESO-1. This is the first study demonstrating a correlation between CTA and prognosis in IHCC. Furthermore, this present retrospective cohort study is limited to relatively small case series (although more selleck chemicals than previous studies); therefore, further validation will be required before these antigens can be tested for targeted immunotherapy. Conclusion In conclusion, our data suggest that the cancer-testis antigens identified in this study might be novel biomarkers and therapeutic targets for patients with IHCC. Acknowledgements This research was supported by grants from National Science Foundation of China (30772017, 30972730), Shanghai Niclosamide Municipal Commission for Science and Technology (08QH14001, 09JC1405400). Electronic supplementary material Additional file 1: Table S1 Clinicopathological characteristics of patients included in this study. a table for the clinicaopathological characteristics of 89 IHCC patients. (DOC
44 KB) References 1. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353–1357.Torin 1 molecular weight PubMedCrossRef 2. Hsing AW, Gao YT, Han TQ, Rashid A, Sakoda LC, Wang BS, Shen MC, Zhang BH, Niwa S, Chen J, Fraumeni JF Jr: Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007, 97:1577–1582.PubMedCrossRef 3. Suri A: Cancer testis antigens–their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006, 6:379–389.PubMedCrossRef 4. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly HK, Talib S, Weinhold KJ: MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 1996, 56:16–20.PubMed 5. Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014–2021.PubMedCrossRef 6.